Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended-spectrum-β-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 495-501

  Waltner Toews, Rebecca I ^a,d   Paterson, David L ^a,b   Qureshi, Zubair A ^a   Sidjabat, Hanna E ^a,b   Adams Haduch, Jennifer M ^a   Shutt, Kathleen A ^a   Jones, Mark ^b   Tian, Guo Bao ^a,c   Pasculle, Anthony W ^a   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE TEM 1; CARBAPENEM; CEFALOTIN; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULFAMETHOXAZOLE; SULTAMICILLIN; TICARCILLIN; TRIMETHOPRIM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; DISK DIFFUSION; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIVARIATE ANALYSIS; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PEPTIC ULCER; PLASMID; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; AMPICILLIN RESISTANCE; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PLASMIDS; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SULBACTAM; YOUNG ADULT;

EID: 78751686231     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00797-10     Document Type: Article

References (39)

1. Akova, M. 2008. Sulbactam-containing β-lactamase inhibitor combinations. Clin. Microbiol. Infect. 14(Suppl. 1):185-188.
2. Al-Hasan, M. N., B. D. Lahr, J. E. Eckel-Passow, and L. M. Baddour. 2009. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J. Antimicrob. Chemother. 64:169-174.
3. Baquero, F., et al. 2009. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg. Infect. (Larchmt.) 10:99-104.
4. Bert, F., C. Branger, and N. Lambert-Zechovsky. 2002. Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J. Antimicrob. Chemother. 50:11-18.
5. Bert, F., et al. 2010. Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J. Clin. Microbiol. 48:2709-2714.
6. Bradford, P. A., et al. 2004. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitorresistant TEM-30 β-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
7. Bukh, A. S., et al. 2009. Escherichia coli phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10 year population-based study in Denmark. J. Antimicrob. Chemother. 64:163-168.
8. Canton, R., M. I. Morosini, O. M. de la Maza, and E. G. de la Pedrosa. 2008. IRT and CMT β-lactamases and inhibitor resistance. Clin. Microbiol. Infect. 14(Suppl. 1):53-62.
9. Clermont, O., S. Bonacorsi, and E. Bingen. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66:4555-4558.
10. Clermont, O., et al. 2009. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J. Antimicrob. Chemother. 64:274-277.
11. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Cooke, N. M., S. G. Smith, M. Kelleher, and T. R. Rogers. 2010. Major differences exist in frequencies of virulence factors and multidrug resistance between community and nosocomial Escherichia coli bloodstream isolates. J. Clin. Microbiol. 48:1099-1104.
13. de Oliveira Garcia, D., et al. 2008. Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. Antimicrob. Agents Chemother. 52:1790-1793.
14. Eagye, K. J., J. L. Kuti, C. A. Sutherland, H. Christensen, and D. P. Nicolau. 2009. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin. Ther. 31:2678-2688.
15. Firsov, A. A., et al. 1996. Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob. Agents Chemother. 40:734-738.
16. Johnson, J. R., et al. 2009. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob. Agents Chemother. 53:2733-2739.
17. Kaye, K. S., et al. 2004. Variety of β-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States. Antimicrob. Agents Chemother. 48:1520-1525.
18. Kaye, K. S., A. D. Harris, H. Gold, and Y. Carmeli. 2000. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Antimicrob. Agents Chemother. 44:1004-1009.
19. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
20. Kruger, T., et al. 2004. Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob. Agents Chemother. 48:4263-4270.
21. TEM genes and their relationship to β-lactam resistance. Antimicrob. Agents Chemother. 46:4035-4037.
22. Lee, C., J. Kim, S. G. Shin, and S. Hwang. 2006. Absolute and relative QPCR quantification of plasmid copy number in Escherichia coli. J. Biotechnol. 123:273-280.
23. Leflon-Guibout, V., et al. 2008. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J. Clin. Microbiol. 46:3900-3905.
24. TEM genes. Antimicrob. Agents Chemother. 44:2709-2714.
25. ΔΔCT method. Methods 25:402-408.
26. Martin, O., et al. 2010. Population analysis and epidemiological features of inhibitor-resistant-TEM-β-lactamase-producing Escherichia coli isolates from both community and hospital settings in Madrid, Spain. J. Clin. Microbiol. 48:2368-2372.
27. Meagher, A. K., A. Forrest, C. R. Rayner, M. C. Birmingham, and J. J. Schentag. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553.
28. Papp-Wallace, K. M., et al. 2010. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob. Agents Chemother. 54:890-897.
29. Perez-Perez, F. J., and N. D. Hanson. 2002. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40:2153-2162.
30. Reguera, J. A., F. Baquero, J. C. Perez-Diaz, and J. L. Martinez. 1991. Factors determining resistance to β-lactam combined with β-lactamase inhibitors in Escherichia coli. J. Antimicrob. Chemother. 27:569-575.
31. Ribot, E. M., et al. 2006. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog. Dis. 3:59-67.
32. Sanders, C. C., and W. E. Sanders, Jr. 1992. β-Lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin. Infect. Dis. 15:824-839.
33. Sannes, M. R., M. A. Kuskowski, K. Owens, A. Gajewski, and J. R. Johnson. 2004. Virulence factor profiles and phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control subjects. J. Infect. Dis. 190:2121-2128.
34. Sidjabat, H. E., et al. 2009. Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. Clin. Infect. Dis. 48:739-744.
35. Sirot, D., et al. 1994. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to β-lactamase inhibitors. J. Antimicrob. Chemother. 33:1117-1126.
36. Stapleton, P., et al. 1995. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob. Agents Chemother. 39:2478-2483.
37. Tenover, F. C., et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
38. Wu, P. J., K. Shannon, and I. Phillips. 1994. Effect of hyperproduction of TEM-1 β-lactamase on in vitro susceptibility of Escherichia coli to β-lactam antibiotics. Antimicrob. Agents Chemother. 38:494-498.
39. Zhou, X. Y., F. Bordon, D. Sirot, M. D. Kitzis, and L. Gutmann. 1994. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhibitors. Antimicrob. Agents Chemother. 38:1085-1089.